报价延迟最少15分钟:2025/09/12 04:15 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.92
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.57/--
|
|
企业价值
719.61M
|
| 资产负债 |
|
每股账面净值
4.48
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
155.84M
|
|
每股收益
0.76
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/12 04:15 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States. |
